A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy

ConclusionsThis case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologous CAR T cells, thus may be one possible regimen before the era of off-the-shelf “universal” CAR T cell therapy.Trial registrationChiCTR-OPN-16008526.http://www.chictr.org.cn/showproj.aspx?proj=13798; ChiCTR1800019385.http://www.chictr.org.cn/showproj.aspx?proj=32805; ChiCTR1800019449.http://www.chictr.org.cn/showproj.aspx?proj=32778.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research